<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Atovaquone and proguanil: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Atovaquone and proguanil: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Atovaquone and proguanil: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11069" href="/d/html/11069.html" rel="external">see "Atovaquone and proguanil: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="15548" href="/d/html/15548.html" rel="external">see "Atovaquone and proguanil: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F137595"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Malarone</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911927"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Malarone;</li>
<li>Malarone Pediatric</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F137614"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antimalarial Agent</li></ul></div>
<div class="block doa drugH1Div" id="F137598"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b917b469-9f40-453d-845b-8105134d59ae">Malaria, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, prophylaxis</b>: <b>Oral:</b> 1 tablet (atovaquone 250 mg/proguanil 100 mg <b>per tablet</b>) once daily; start 1 to 2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after returning (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="907db476-c453-431b-8e3f-050c1461baaf">Malaria, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, treatment: Oral:</b> 4 tablets (atovaquone 250 mg/proguanil 100 mg <b>per tablet</b>) once daily for 3 days.<b> Note:</b> If used for <i>P. vivax</i> or <i>P. ovale</i>, use in combination with primaquine. If used for severe malaria (after completion of IV therapy), use full 3-day schedule (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990776"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">CrCl ≥30 mL/minute: No dosage adjustment necessary. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">CrCl &lt;30 mL/minute:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Prophylaxis: Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Treatment: No dosage adjustment necessary; however, use with extreme caution and only if the benefits outweigh the risks.</p></div>
<div class="block doha drugH1Div" id="F50987947"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild-to-moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment; No dosage adjustment provided in manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F137599"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F137608"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="15548" href="/d/html/15548.html" rel="external">see "Atovaquone and proguanil: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;">
<b>Note: </b>Tablets are available in different strengths (pediatric and adult tablets) and both may be used in pediatric patients depending upon patient weight; use extra precaution</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3cbb6b4b-3f07-4e7b-b333-89060573a9c0">Malaria; prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria; prevention</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2018'])">Ref</a></span>): Infants, Children, and Adolescents: Begin 1 to 2 days prior to entering a malaria-endemic area, continue throughout the stay and for 7 days after leaving area: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">5 to 8 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 31.25 mg atovaquone/12.5 mg proguanil (<sup>1</sup>/<sub>2</sub> tablet) once daily</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;8 to 10 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 46.88 mg atovaquone/18.75 mg proguanil (<sup>3</sup>/<sub>4</sub> tablet) once daily</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;10 to 20 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 62.5 mg atovaquone/25 mg proguanil (1 tablet) once daily</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;20 to 30 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 125 mg atovaquone/50 mg proguanil (2 tablets) once daily</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;30 to 40 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 187.5 mg atovaquone/75 mg proguanil (3 tablets) once daily</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 250 mg atovaquone/100 mg proguanil (1 tablet) once daily</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2a124811-7fef-4db5-a79b-db2094c86a85">Malaria; treatment, uncomplicated P. falciparum or P. vivax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>Malaria; treatment, uncomplicated <i>P. falciparum or P. vivax</i></b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2013']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2013'])">Ref</a></span>): Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">5 to 8 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 125 mg atovaquone/50 mg proguanil (2 tablets) once daily for 3 doses</p>
<p style="text-indent:-2em;margin-left:6em;">9 to 10 kg: Pediatric tablet (62.5 mg atovaquone/25 mg proguanil per tablet): 187.5 mg atovaquone/75 mg proguanil (3 tablets) once daily for 3 doses</p>
<p style="text-indent:-2em;margin-left:6em;">11 to 20 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 250 mg atovaquone/100 mg proguanil (1 tablet) once daily for 3 doses</p>
<p style="text-indent:-2em;margin-left:6em;">21 to 30 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 500 mg atovaquone/proguanil/200 mg proguanil (2 tablets) once daily for 3 doses</p>
<p style="text-indent:-2em;margin-left:6em;">31 to 40 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 750 mg atovaquone/300 mg proguanil (3 tablets) once daily for 3 doses</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;40 kg: Adult tablet (250 mg atovaquone/100 mg proguanil per tablet): 1,000 mg atovaquone/400 mg proguanil (4 tablets) once daily for 3 doses</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51065158"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: Should not be used as prophylaxis in severe renal impairment (CrCl &lt;30 mL/minute) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2018'])">Ref</a></span>). For treatment of malaria, alternative regimens should be used in patients with CrCl &lt;30 mL/minute unless benefits outweigh the risks. No dosage adjustment required in mild to moderate renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51065159"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;margin-left:0em;display:inline">No dosage adjustment required in mild to moderate hepatic impairment. No data available for use in severe hepatic impairment.</p></div>
<div class="block adr drugH1Div" id="F137567"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. The following adverse reactions were reported in patients being treated for malaria. When used for prophylaxis, reactions are similar to those seen with placebo.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (17%), nausea (12%), vomiting (children: 10% to 13%; adults: 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (27%; increased liver function test values typically normalized after ~ 4 weeks), increased serum AST (17%; increased liver function test values typically normalized after ~4 weeks)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (10%), dizziness (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (children: 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (children: 6%; adults: 8%), anorexia (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis (rare), anemia (rare), angioedema, cholestasis, erythema multiforme (rare), hallucination, hepatic failure (case report), hepatitis (rare), neutropenia, pancytopenia (with severe renal impairment), psychotic reaction (rare), seizure (rare), skin photosensitivity, skin rash, Stevens-Johnson syndrome (rare), stomatitis, urticaria, vasculitis (rare)</p></div>
<div class="block coi drugH1Div" id="F137580"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to atovaquone, proguanil, or any component of the formulation; prophylactic use in severe renal impairment (CrCl &lt;30 mL/minute)</p></div>
<div class="block war drugH1Div" id="F137564"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Hepatic effects: Increased transaminase levels and hepatitis have been reported with prophylactic use; single case report of hepatic failure requiring transplantation documented. Monitor closely and use caution in patients with existing hepatic impairment. Elevations in AST/ALT may persist for up to 4 weeks following treatment (Looareesuwan, 1999).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Diarrhea/vomiting: Absorption of atovaquone may be decreased in patients who have diarrhea or vomiting; monitor closely and consider use of an antiemetic. If severe, consider use of an alternative antimalarial.</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Malaria: Appropriate use: Not indicated for cerebral malaria or other severe manifestations of complicated malaria. Delayed cases of <i>P. falciparum</i> malaria may occur after stopping prophylaxis; travelers returning from endemic areas who develop febrile illnesses should be evaluated for malaria. Recrudescent infections or infections following prophylaxis with this agent should be treated with alternative agent(s). </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Renal impairment: Use with caution in patients with preexisting renal disease. May use with caution for treatment of malaria in patients with severe renal impairment (CrCl &lt;30 mL/minute) if benefit outweighs risk. Contraindicated for prophylactic use in severe renal impairment due to the risk of pancytopenia in patients with severe renal impairment treated with proguanil.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">• Obesity: Treatment failures have been reported in patients &gt;100 kg (case reports); follow-up monitoring is recommended (Durand, 2008).</p></div>
<div class="block foc drugH1Div" id="F137574"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Malarone: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral [pediatric]:</p>
<p style="text-indent:-2em;margin-left:4em;">Malarone: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p></div>
<div class="block geq drugH1Div" id="F137560"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F137581"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Atovaquone-Proguanil HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5-25 mg (per each): $2.54 - $2.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250-100 mg (per each): $6.86 - $7.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Malarone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5-25 mg (per each): $2.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250-100 mg (per each): $8.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F55209951"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Malarone: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Atovaquone 250 mg and proguanil hydrochloride 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet, Oral [pediatric]:</p>
<p style="text-indent:-2em;margin-left:4em;">Malarone: Atovaquone 62.5 mg and proguanil hydrochloride 25 mg</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: Atovaquone 62.5 mg and proguanil 25 mg</p></div>
<div class="block adm drugH1Div" id="F137577"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with food or milk-based drink at the same time each day. If vomiting occurs within 1 hour of administration, repeat the dose. For patients who have difficulty swallowing tablets, tablets may be crushed and mixed with condensed milk just prior to administration.</p></div>
<div class="block admp drugH1Div" id="F52612272"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or milk at the same time each day. If vomiting occurs within 30 minutes of administration, repeat the dose. Tablets are not palatable if chewed due to bitter taste. For children who have difficulty swallowing tablets, tablets may be crushed and mixed with condensed milk just prior to administration.</p></div>
<div class="block use drugH1Div" id="F137575"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria, prophylaxis:</b> Prophylaxis of <i>Plasmodium falciparum</i> malaria, including areas where chloroquine resistance has been reported. <b>Note:</b> CDC also recommends atovaquone/proguanil as prophylaxis for other <i>Plasmodium</i> species (CDC Yellow Book 2024).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria<i>,</i> treatment:</b> Treatment of acute, uncomplicated <i>P. falciparum</i> malaria.<b> Note:</b> Guidelines also recommend atovaquone/proguanil for nonfalciparum malaria and as oral treatment for severe malaria after completion of IV therapy or as interim therapy pending IV therapy (CDC 2023).</p></div>
<div class="block mst drugH1Div" id="F28800043"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Malarone may be confused with mefloquine</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F137609"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F137569"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: May enhance the adverse/toxic effect of Atovaquone. Specifically, the risk for extrapyramidal side effects may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amodiaquine: May enhance the adverse/toxic effect of Proguanil. Specifically, the risk for extrapyramidal side effects may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May decrease the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Artemether and Lumefantrine.  Management: Artemether/lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option. If combined, monitor patients for increased toxicities of both agents, including QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ChlorproMAZINE: Antimalarial Agents may increase the serum concentration of ChlorproMAZINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Strong) may increase the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Consider avoidance of this combination when possible. If combined, closely monitor for signs/symptoms of hemolytic reactions. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to the use of atovaquone with efavirenz when possible.  If this combination must be used, monitor for evidence of reduced atovaquone clinical effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ethinyl Estradiol-Containing Products: May decrease serum concentrations of the active metabolite(s) of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: Atovaquone may increase the serum concentration of Etoposide.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: Atovaquone may increase the serum concentration of Etoposide Phosphate.  Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Atovaquone may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May decrease the serum concentration of Atovaquone. Management: Consider alternatives to metoclopramide when possible; atovaquone should only be used with metoclopramide if no other antiemetics are available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pyrimethamine: May enhance the adverse/toxic effect of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: Atovaquone may decrease the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Atovaquone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: Atovaquone may increase the serum concentration of RifAMPin. RifAMPin may decrease the serum concentration of Atovaquone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Proguanil.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracycline (Systemic): May decrease the serum concentration of Atovaquone.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Proguanil may diminish the therapeutic effect of Typhoid Vaccine. This applies only to the oral (live) typhoid vaccine.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with proguanil. When possible, proguanil should not be started within 10 days of the last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Warfarin: Proguanil may enhance the anticoagulant effect of Warfarin. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F137591"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Atovaquone taken with dietary fat significantly increases the rate and extent of absorption; AUC is increased 2-3 times and C<sub>max</sub> is increased 5 times as compared to administration during a fasted state. Management: Administer with food or milk-based drink at the same time each day.</p></div>
<div class="block rep_considerations drugH1Div" id="F58912649"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Patients who are likely to become pregnant are advised to avoid travel to malaria-risk areas. When travel is unavoidable, precautions should be taken to avoid mosquito bites and effective prophylactic medications should be used. Medications considered acceptable for the prophylaxis of malaria during pregnancy may be used in patients trying to conceive. Atovaquone/proguanil is not recommended for use in pregnant patients (CDC 2023; CDC Yellow Book 2024).</p></div>
<div class="block pri drugH1Div" id="F137582"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following maternal use of atovaquone and proguanil during pregnancy are limited (Andrejko 2019; Gutman 2019; Mayer 2018).</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of atovaquone and proguanil may be altered during pregnancy (Burger 2016).</p>
<p style="text-indent:0em;margin-top:2em;">Malaria infection during pregnancy may be more severe than in nonpregnant people and has a high risk of maternal and perinatal morbidity and mortality. Malaria infection during pregnancy can lead to miscarriage, premature delivery, low birth weight, congenital infection, and/or perinatal death. Therefore, pregnant patients are advised to avoid travel to malaria-risk areas. When travel is unavoidable, pregnant patients should take precautions to avoid mosquito bites and use effective prophylactic medications (CDC 2023; CDC Yellow Book 2024).</p>
<p style="text-indent:0em;margin-top:2em;">Due to limited data, atovaquone/proguanil is not preferred for use during pregnancy. However, atovaquone/proguanil may be used as an alternative treatment of malaria caused by chloroquine-resistant <i>P. falciparum</i> in pregnant patients when other treatment options are not available or not being tolerated; consult current CDC guidelines (CDC 2023).</p></div>
<div class="block brc drugH1Div" id="F9760124"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Proguanil is present in breast milk; excretion of atovaquone is not known.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Other sources note that this combination is not recommended if breastfeeding infants &lt;5 kg (safety data are limited concerning therapeutic use in infants &lt;5 kg) (Boggild 2007; CDC Yellow Book 2024).</p></div>
<div class="block dic drugH1Div" id="F137583"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Must be taken with food or milk-based drink.</p></div>
<div class="block mop drugH1Div" id="F9760127"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Liver and renal function; closely monitor response to treatment in patients with vomiting or diarrhea and in patients &gt;100 kg (Durand, 2008)</p></div>
<div class="block pha drugH1Div" id="F137563"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Atovaquone: Selectively inhibits parasite mitochondrial electron transport. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Proguanil: The metabolite cycloguanil inhibits dihydrofolate reductase, disrupting deoxythymidylate synthesis. Together, atovaquone/cycloguanil affect the erythrocytic and exoerythrocytic stages of development.</p></div>
<div class="block phk drugH1Div" id="F137579"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atovaquone: The rate and extent of absorption is increased when administered with dietary fat. </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proguanil: Extensive </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atovaquone: Children and Adults: ~8.8 L/kg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proguanil: Children &gt;15 years and Adults and 31-110 kg: 1617-2502 L; Pediatric patients ≤15 years and 11-56 kg: 462-966 L; concentrated in erythrocytes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atovaquone: &gt;99%</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proguanil: 75%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Proguanil: Hepatic to active metabolites, cycloguanil (via CYP2C19) and 4-chlorophenylbiguanide</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Atovaquone/proguanil: 23% when administered with food</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atovaquone: 2-3 days (adults), 1-2 days (children)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proguanil: 12-21 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion:</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atovaquone: Feces (&gt;94% as unchanged drug); urine (&lt;0.6%)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Proguanil: Urine (40% to 60%)</p></div>
<div class="block phksp drugH1Div" id="F51220455"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: In patients with moderate renal impairment (CrCl 30-50 mL/minute), mean oral clearance for proguanil was reduced by ~35% compared with patients with normal renal function CrCl &gt;80 mL/minute). In patients with severe renal impairment (CrCl &lt;30 mL/minute), atovaquone C<sub>max</sub> and AUC are reduced, but the elimination half-lives for proguanil and cycloguanil are prolonged, with corresponding increases in AUC, resulting in the potential of drug accumulation and toxicity with repeated dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Atovaquone elimination half-life was increased in patients with moderate hepatic impairment. Proguanil AUC, C<sub>max</sub>, and elimination half-life were increased and cycloguanil (metabolite) AUC and C<sub>max</sub> were decreased and elimination half-life was increased in patients with mild hepatic impairment. Proguanil AUC and C<sub>max</sub> were increased in patients with moderate hepatic impairment. The pharmacokinetics of atovaquone, proguanil, and cycloguanil have not been studied in patients with severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC was increased, T<sub>max</sub> was longer, and elimination half-life was longer in elderly subjects (~15 hours) compared to younger subjects (~8 hours).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F137584"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Malaglen | Malanil | Malarone</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon/Proguanilhydrochlorid STADA | Malarone</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Malarone | Promozio</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/proguanil EG | Atovaquone/proguanil mylan | Atovaquone/proguanil teva | Malaprotec | Malarone | Provaquoneg</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Malanil</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon plus | Atovaquon proguanil mepha | Malarone</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon/Proguanil HCl glenmark | Atovaquon/Proguanilhydrochlorid AL | Atovaquon/Proguanilhydrochlorid ratiopharm | Atovaquon/Proguanilhydrochlorid STADA | Malacomp | Malarone</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atovacuona hidrocloruro de proguanil viso farmaceutica | Atovacuona/hidrocloruro de proguanil mylan | Atovacuona/hidrocloruro de proguanil sandoz | Atovacuona/hidrocloruro de proguanil teva | Malarone</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/Proguanil ratiopharm | Malarone | Rumbabor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/proguanil biogaran | Atovaquone/proguanil EG | Atovaquone/proguanil mylan | Atovaquone/proguanil sandoz | Atovaquone/proguanil sigma tau | Atovaquone/proguanil zentiva | Malarone</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/proguanil hydrochloride | Mafamoz | Malarone | Maloff Protect | Reprapog</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/proguanil hydrochloride | Malarone</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone e proguanile mylan generics | Malarone</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Malaglen | Malanil</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Malalone | Malarone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/proguanil EG | Atovaquone/Proguanil ratiopharm | Malaprotec | Malarone | Provaquoneg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Malanil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon/proguanil amarox | Atovaquon/Proguanil HCL CF | Atovaquon/Proguanil HCl Mylan | Atovaquon/Proguanil HCl Sandoz | Atovaquon/Proguanil HCl Teva | Atovaquon/Proguanilhydrochloride | Malarone</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Malarone | Provaqomyl</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atofal | Atofal padiatric | Atpro | Atpro pediatric | Laro | Malaron | Malaron kids | Tovanil | Tovanil pediatric</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Falcimar | Malarone</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Atovaquon/Proguanil hcl | Atovaquone and proguanil hcl | Atovaquone and proguanil hydrochloride | Malarone</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Malanil | Malarone</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Atovaquone/proguanil Glenmark | Malarone</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atovakvon/proguanil glenmark | Horisto | Malarone | Malastad | Provaqomyl</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Malanil | Malarone</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Malanil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Malarone</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Malanil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Atapro | Atovaquone/proguanil Glenmark | Malagen | Malanil | Malateq | Mozitec | Numal</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Malanil</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30654041">
<a name="30654041"></a>Andrejko KL, Mayer RC, Kovacs S, et al. The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: a systematic review. <i>Travel Med Infect Dis</i>. 2019;27:20-26. doi: 10.1016/j.tmaid.2019.01.008.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/30654041/pubmed" id="30654041" target="_blank">30654041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17297027">
<a name="17297027"></a>Boggild AK, Parise ME, Lewis LS, et al, “Atovaquone-Proguanil: Report From The CDC Expert Meeting On Malaria Chemoprophylaxis (II),” <i>Am J Trop Med Hyg</i>, 2007, 76(2):208-23.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/17297027/pubmed" id="17297027" target="_blank">17297027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26891915">
<a name="26891915"></a>Burger RJ, Visser BJ, Grobusch MP, van Vugt M. The influence of pregnancy on the pharmacokinetic properties of artemisinin combination therapy (ACT): a systematic review. <i>Malar J</i>. 2016;15:99. doi: 10.1186/s12936-016-1160-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/26891915/pubmed" id="26891915" target="_blank">26891915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2019">
<a name="CDC.2019"></a>Centers for Disease Control and Prevention (CDC). <i>CDC Yellow Book 2024: Health Information for International Travel</i>. Oxford University Press; 2023. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/malaria</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2018">
<a name="CDC.2018"></a>Centers for Disease Control and Prevention. <i>CDC Yellow Book 2018: Health Information for International Travel</i>. New York: Oxford University Press; 2017. <a href="https://wwwnc.cdc.gov/travel/yellowbook/2018/table-of-contents" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2018/table-of-contents</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19730409">
<a name="19730409"></a>Centers for Disease Control and Prevention (CDC), "Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children," <i>MMWR Recomm Rep</i>, 2009, 58(RR-11):1-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/19730409/pubmed" id="19730409" target="_blank">19730409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2013">
<a name="CDC.2013"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria (guidelines for clinicians). <i>Centers for Disease Control and Prevention.</i> 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated June 28, 2023. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18258131">
<a name="18258131"></a>Durand R, Prendki V, Cailhol J, et al, “<i>Plasmodium falciparum</i> Malaria and Atovaquone-Proguanil Treatment Failure,” <i>Emerg Infect Dis</i>, 2008, 14(2):320-2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/18258131/pubmed" id="18258131" target="_blank">18258131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31747537">
<a name="31747537"></a>Gutman JR, Hall C, Khodr ZG, et al. Atovaquone-proguanil exposure in pregnancy and risk for adverse fetal and infant outcomes: a retrospective analysis. <i>Travel Med Infect Dis</i>. 2019;32:101519. doi:10.1016/j.tmaid.2019.101519<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/31747537/pubmed" id="31747537" target="_blank">31747537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10348224">
<a name="10348224"></a>Looareesuwan S, Wilairatana P, Chalermarut K, et al. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute <i>Plasmodium falciparum</i> malaria in Thailand. <i>Am J Trop Med Hyg</i>. 1999;60(4):526-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/10348224/pubmed" id="10348224" target="_blank">10348224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Malarone.1">
<a name="Malarone.1"></a>Malarone (atovaquone and proguanil hydrochloride) tablets and pediatric tablets [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Malarone.2">
<a name="Malarone.2"></a>Malarone (atovaquone and proguanil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30544231">
<a name="30544231"></a>Mayer RC, Tan KR, Gutman JR. Safety of atovaquone-proguanil during pregnancy [published online ahead of print December 13, 2018]. <i>J Travel Med</i>. doi: 10.1093/jtm/tay138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/30544231/pubmed" id="30544231" target="_blank">30544231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21973268">
<a name="21973268"></a>Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. <i>Clin Pharmacokinet</i>. 2011;50(11):705-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/atovaquone-and-proguanil-drug-information/abstract-text/21973268/pubmed" id="21973268" target="_blank">21973268</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8704 Version 215.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
